OraSure Technologies announced it received FDA Emergency Use Authorization (EUA) for its OraQuick Ebola 2.0 Rapid Antigen Test. This authorization allows the company to market and sell the test for detecting Ebola in live patients and cadaveric oral fluid, potentially expanding its market reach and revenue streams in the public health sector.
OraSure Technologies (OSUR) has secured an Emergency Use Authorization from the FDA for its OraQuick Ebola 2.0 Rapid Antigen Test. This authorization is a significant corporate catalyst as it allows OSUR to commercialize a new diagnostic product for a critical public health need. The test's ability to detect all four known Ebola viruses in both live patients and cadaveric samples expands its utility and potential market. This development could lead to increased revenue for OSUR in the short to medium term, particularly if there are future Ebola outbreaks or increased demand for rapid diagnostic tools. For traders, this represents an opportunity for OSUR, as the company strengthens its position in the infectious disease diagnostics market.